Molecular Partners (NASDAQ:MOLN) Trading Down 0.6% – What’s Next?

Shares of Molecular Partners AG (NASDAQ:MOLN) were down 0.6% on Tuesday . The company traded as low as $5.36 and last traded at $5.36. Approximately 6,640 shares changed hands during trading, a decline of 12% from the average daily volume of 7,505 shares. The stock had previously closed at $5.39.

Analyst Upgrades and Downgrades

Separately, Leerink Partnrs upgraded shares of Molecular Partners to a “strong-buy” rating in a research report on Monday, October 7th.

Molecular Partners Stock Performance

The firm has a fifty day simple moving average of $5.44 and a 200 day simple moving average of $5.75. The company has a market cap of $216.35 million, a PE ratio of -2.49 and a beta of 1.05.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.